145 related articles for article (PubMed ID: 35732976)
21. A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.
Bergua JM; Montesinos P; Martinez-Cuadrón D; Fernández-Abellán P; Serrano J; Sayas MJ; Prieto-Fernandez J; García R; García-Huerta AJ; Barrios M; Benavente C; Pérez-Encinas M; Simiele A; Rodríguez-Macias G; Herrera-Puente P; Rodríguez-Veiga R; Martínez-Sánchez MP; Amador-Barciela ML; Riaza-Grau R; Sanz MA;
Br J Haematol; 2016 Sep; 174(5):700-10. PubMed ID: 27118319
[TBL] [Abstract][Full Text] [Related]
22. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study.
Lachowiez CA; Reville PK; Kantarjian H; Jabbour E; Borthakur G; Daver N; Loghavi S; Furudate K; Xiao L; Pierce S; Short NJ; Maiti A; Yilmaz M; Sasaki K; Takahashi K; Konopleva M; Pemmaraju N; Popat U; Shpall E; Garcia-Manero G; Ravandi F; DiNardo CD; Kadia TM
Lancet Haematol; 2022 May; 9(5):e350-e360. PubMed ID: 35483396
[TBL] [Abstract][Full Text] [Related]
23. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.
Gaut D; Burkenroad A; Duong T; Feammelli J; Sasine J; Schiller G
Leuk Res; 2020 Mar; 90():106314. PubMed ID: 32035355
[TBL] [Abstract][Full Text] [Related]
24. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O
Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237
[TBL] [Abstract][Full Text] [Related]
25. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Schuler E; Wagner-Drouet EM; Ajib S; Bug G; Crysandt M; Dressler S; Hausmann A; Heidenreich D; Hirschbühl K; Hoepting M; Jost E; Kaivers J; Klein S; Koldehoff M; Kordelas L; Kriege O; Müller LP; Rautenberg C; Schaffrath J; Schmid C; Wolff D; Haas R; Bornhäuser M; Schroeder T; Kobbe G;
Ann Hematol; 2021 Apr; 100(4):959-968. PubMed ID: 33191481
[TBL] [Abstract][Full Text] [Related]
26. Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy.
Yamauchi T; Yoshida C; Usuki K; Takada S; Matsumura I; Dobashi N; Miyazaki Y; Miyamoto T; Iida H; Asou N; Kuroda J; Ichikawa S; Komatsu N; Mendes W; Honda H; Okubo S; Kurokawa M; Jiang Q; Wei A; Ishizawa K
Jpn J Clin Oncol; 2021 Aug; 51(9):1372-1382. PubMed ID: 34322703
[TBL] [Abstract][Full Text] [Related]
27. Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report.
Liu B; Narurkar R; Hanmantgad M; Zafar W; Song Y; Liu D
Front Med; 2018 Oct; 12(5):593-599. PubMed ID: 29785506
[TBL] [Abstract][Full Text] [Related]
28. [Analysis of the Efficacy and Prognosis Factors of Acute Myeloid Leukemia with a Combination Therapy of Venetoclax].
Ren CC; Zhang WW; Wu TK; Liu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):104-111. PubMed ID: 38387907
[TBL] [Abstract][Full Text] [Related]
29. Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?
Agarwal S; Kowalski A; Schiffer M; Zhao J; Bewersdorf JP; Zeidan AM
Expert Rev Hematol; 2021 Feb; 14(2):199-210. PubMed ID: 33459064
[TBL] [Abstract][Full Text] [Related]
30. FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies.
Mustafa O; Abdalla K; AlAzmi AA; Elimam N; Abrar MB; Jastaniah W
J Oncol Pharm Pract; 2019 Dec; 25(8):1831-1838. PubMed ID: 30518307
[TBL] [Abstract][Full Text] [Related]
31. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
[TBL] [Abstract][Full Text] [Related]
32. Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia.
Shargian-Alon L; Wolach O; Rozovski U; Yahav D; Sela-Navon M; Rubinstein M; Oniashvilli N; Pasvolsky O; Raanani P; Yeshurun M
Ann Hematol; 2020 Dec; 99(12):2939-2945. PubMed ID: 32892274
[TBL] [Abstract][Full Text] [Related]
33. The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia.
Byrne M; Danielson N; Sengsayadeth S; Rasche A; Culos K; Gatwood K; Wyatt H; Chinratanalab W; Dholaria B; Ferrell PB; Fogo K; Goodman S; Jagasia M; Jayani R; Kassim A; Mohan SR; Savani BN; Strickland SA; Engelhardt BG; Savona M
Am J Hematol; 2020 Sep; 95(9):1006-1014. PubMed ID: 32390196
[TBL] [Abstract][Full Text] [Related]
34. FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients.
Delia M; Pastore D; Carluccio P; Pasciolla C; Ricco A; Rossi AR; Casieri P; Mestice A; Albano F; Specchia G
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):767-773. PubMed ID: 28864170
[TBL] [Abstract][Full Text] [Related]
35. Real world results of venetoclax combined with hypomethylating agents in relapsed/refractory AML.
Ucar MA; Ozet G; Koyuncu MB; Sonmez M; Akidan O; Ayli M; Yildirim M; Pehlivan M; Akkurd DM; Sahin H; Guvenc B; Okan V; Tiftik EN; Akdeniz A; Dincyurek HD; Gunes AK; Dagdas S; Acar HI; Ucar HK; Tombak A
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6557-6565. PubMed ID: 34787859
[TBL] [Abstract][Full Text] [Related]
36. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant.
Bewersdorf JP; Derkach A; Gowda L; Menghrajani K; DeWolf S; Ruiz JD; Ponce DM; Shaffer BC; Tamari R; Young JW; Jakubowski AA; Gyurkocza B; Chan A; Xiao W; Glass J; King AC; Cai SF; Daniyan A; Famulare C; Cuello BM; Podoltsev NA; Roshal M; Giralt S; Perales MA; Seropian S; Cho C; Zeidan AM; Prebet T; Stein EM; Tallman MS; Goldberg AD; Stahl M
Leuk Lymphoma; 2021 Dec; 62(14):3394-3401. PubMed ID: 34477024
[TBL] [Abstract][Full Text] [Related]
37. Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America.
Gómez-De León A; Demichelis-Gómez R; Pinedo-Rodríguez A; Enriquez-Vera D; Flores-Jiménez JA; Ceballos-López AA; Rodríguez-Mejorada M; Herrera Riojas MA; Ovilla-Martínez R; Báez-Islas P; Cota-Rangel X; Neme-Yunes Y; Inclán-Alarcón S; López-Flores NJ; Colunga-Pedraza PR; Rodríguez-Zúñiga AC; Gómez-Almaguer D
Hematology; 2022 Dec; 27(1):249-257. PubMed ID: 35192778
[No Abstract] [Full Text] [Related]
38. Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data.
Hoff FW; Patel PA; Belli AJ; Hansen E; Foss H; Schulte M; Wang CK; Madanat YF
Leuk Lymphoma; 2023 Jun; 64(6):1123-1128. PubMed ID: 37052347
[TBL] [Abstract][Full Text] [Related]
39. Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia.
Sciumè M; Bosi A; Canzi M; Ceparano G; Serpenti F; De Roberto P; Fabris S; Tagliaferri E; Cavallaro F; Onida F; Fracchiolla NS
Front Oncol; 2023; 13():1149298. PubMed ID: 37051529
[TBL] [Abstract][Full Text] [Related]
40. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs.
Masarova L; DiNardo CD; Bose P; Pemmaraju N; Daver NG; Kadia TM; Chifotides HT; Zhou L; Borthakur G; Estrov Z; Konopleva M; Verstovsek S
Blood Adv; 2021 Apr; 5(8):2156-2164. PubMed ID: 33885751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
